...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of clinical rheumatology. >ADAM17: A potential therapeutic target for rheumatoid arthritis?
【24h】

ADAM17: A potential therapeutic target for rheumatoid arthritis?

机译：ADAM17：类风湿关节炎的潜在治疗靶点？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In recent years we have seen a breakthrough in the use of biologies for the treatment of chronic inflammatory diseases. For over 10 years, patients with rheumatoid arthritis have been treated with inhibitors of the cyto-kine TNF-a, such as monoclonal antibodies or a soluble TNF-a receptor protein [1]. More recently, blockade of the IL-6 pathway using a monoclonal antibody against the human IL-6 receptor (IL-6R) has been approved in Japan, Europe and the USA [2]. Many more IL-6-targeting antibodies are in clinical trials or in preclinical development, underlining the growing interest in blockade of the cytokine IL-6 [3], Although the therapeutic success of the TNF-a and IL-6 pathway blockades is impressive, it should be kept in mind that not all patients respond to therapy with a given biologic and that cytokine blockade may lead to an impairment of the immune system [1-3]. Therefore, novel approaches and therapeutic strategies are urgently warranted.
机译：近年来，我们已经看到了在使用生物制剂治疗慢性炎性疾病方面的突破。十多年来，类风湿关节炎患者已经接受了细胞因子TNF-α抑制剂的治疗，例如单克隆抗体或可溶性TNF-α受体蛋白[1]。最近，在日本，欧洲和美国已批准使用抗人IL-6受体（IL-6R）的单克隆抗体阻断IL-6途径[2]。更多的靶向IL-6的抗体正在临床试验或临床前开发中，突显出人们对阻断细胞因子IL-6的兴趣日益增长[3]，尽管TNF-a和IL-6途径阻断剂的治疗成功令人印象深刻，请记住，并非所有患者都对给定的生物制剂治疗有反应，并且细胞因子的阻断可能导致免疫系统受损[1-3]。因此，迫切需要新的方法和治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号